scholarly journals Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials

2016 ◽  
Vol 7 (4) ◽  
pp. 544-554 ◽  
Author(s):  
Atsunori Kashiwagi ◽  
Satoshi Yoshida ◽  
Ichiro Nakamura ◽  
Kenichi Kazuta ◽  
Eiji Ueyama ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Clinical Trials ◽  
Body Mass ◽  
Subgroup Analysis ◽  
Randomized Clinical Trials ◽  
Japanese Patients ◽  
Efficacy And Safety

Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials

2017 ◽  
Vol 43 (1) ◽  
pp. 48-58 ◽  
Author(s):  
M.B. Rehman ◽  
B.V. Tudrej ◽  
J. Soustre ◽  
M. Buisson ◽  
P. Archambault ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Efficacy And Safety

scholarly journals Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference

2011 ◽  
Vol 4 ◽  
pp. CMED.S5976 ◽  
Author(s):  
Daisuke Yabe ◽  
Yutaka Seino
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Glucagon Secretion ◽  
Japanese Patients ◽  
Global Perspective ◽  
Daily Injection ◽  
Efficacy And Safety ◽  
New Class ◽  
Glucagon Like Peptide 1

Incretin-based therapies have been gaining much attention recently as a new class of therapeutics for type 2 diabetes worldwide. Among them, glucagon-like peptide-1 receptor agonist liraglutide has been rapidly increasing its global usage. Once daily injection of liraglutide significantly ameliorates glycemic control in patients with type 2 diabetes by enhancing insulin secretion and suppressing glucagon secretion glucose-dependently. Liraglutide delays gastric emptying and suppresses food intakes, both of which contribute to glucose lowering and weight reduction. Efficacy and safety of liraglutide in management of type 2 diabetes have been well documented in several key clinical trials such as series of phase 3 Liraglutide Effect and Action in Diabetes (LEAD) trials, and the liraglutide-versus-sitagliptin trial. Recent two trials dealing with monotherapy and sulfonylurea combination therapy on Japanese patients with type 2 diabetes furthermore indicate liraglutide's effectiveness in non-obese diabetes. In this review, we summarize results from such clinical trials, and discuss efficacy and safety of liraglutide in management of type 2 diabetes in various countries, along with a pitfall of liraglutide usage in real clinical setting.

Self-reported rate of eating is significantly associated with body mass index in Japanese patients with type 2 diabetes. Japan Diabetes Clinical Data Management Study Group (JDDM26)

Appetite ◽  
2012 ◽  
Vol 59 (2) ◽  
pp. 252-255 ◽  
Author(s):  
Aki Saito ◽  
Koichi Kawai ◽  
Morifumi Yanagisawa ◽  
Hiroki Yokoyama ◽  
Nobuichi Kuribayashi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Data Management ◽  
Body Mass ◽  
Clinical Data ◽  
Japanese Patients ◽  
Study Group ◽  
Management Study
Sign in / Sign up

Export Citation Format

Share Document